STOCK TITAN

NLS Pharmaceutics AG - NLSPW STOCK NEWS

Welcome to our dedicated page for NLS Pharmaceutics news (Ticker: NLSPW), a resource for investors and traders seeking the latest updates and insights on NLS Pharmaceutics stock.

NLS Pharmaceutics Ltd is a biopharmaceutical company specialized in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for neurobehavioral and neurocognitive disorders, with tangible assets held in the United States. Their lead products, Quilience, to treat narcolepsy, and Nolazol, to treat ADHD, are at the forefront of their innovative solutions.

Rhea-AI Summary

NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company specializing in treatments for rare and complex CNS disorders, announced a registered direct offering of 3,277,750 common shares at $0.24 per share. This offering is expected to close around July 1, 2024, subject to customary conditions. Additionally, NLS will issue unregistered warrants for the same number of shares, exercisable immediately at $0.24 per share and expiring in five years. The gross proceeds of $786,660 will support working capital, R&D, and strategic expansion. H.C. Wainwright & Co. is acting as the exclusive placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.58%
Tags
-
Rhea-AI Summary

NLS Pharmaceutics (NASDAQ:NLSP) has announced promising preclinical results from in vitro studies targeting alpha-synuclein (A53T mutation) to treat Parkinson's Disease (PD). Utilizing the 'Alpha-Synuclein (A53T) Genetic Cell-Based Agonist Neurite Outgrowth Assay' by Eurofins, various compounds demonstrated positive effects on neurite outgrowth, indicating potential neuronal health benefits.

AEX-23 showed significant OX1R agonist activity and positive neurite outgrowth. AEX-19 showed benefits at low concentrations, increasing CTSD activity and imparting neuroprotective effects. AEX-24 enhanced CTSD activity, suggesting a role in alpha-synuclein degradation.

NLS plans to develop AEX-230 and AEX-231, targeting cathepsins involved in neurodegenerative disorders. Further preclinical and in vivo studies are needed to optimize dosing and assess long-term safety and efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.15%
Tags
-
Rhea-AI Summary

NLS Pharmaceutics announced that the Nasdaq Hearings Panel has granted the company an extension until October 14, 2024, to meet listing requirements for the Nasdaq Capital Market. The company must comply with a minimum bid price of $1.00 per share and maintain at least $2,500,000 in stockholders' equity, as per Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). Previously, NLS received notification from Nasdaq that it failed to meet these criteria, prompting a hearing on June 4, 2024. Despite the extension, there are no guarantees that NLS will achieve compliance by the deadlines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
Rhea-AI Summary

NLS Pharmaceutics, a clinical-stage biopharmaceutical company, has announced a new patent application for dual orexin receptor agonists (DOXA), developed with Aexon Labs, targeting narcolepsy and neurodegenerative diseases like Parkinson's. These non-sulfonamide compounds are designed to reduce side effects and improve patient safety. The molecules enhance neurotransmitter release and protect neuronal health by modulating orexin receptors and inhibiting cathepsin H (CTSH), offering potential therapeutic benefits for sleep regulation and neurodegeneration. This patent represents a significant advancement in addressing unmet medical needs in both narcolepsy and neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
-
Rhea-AI Summary

NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary

NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
Rhea-AI Summary
NLS Pharmaceutics received a delisting determination from Nasdaq due to failing to maintain a $1 bid price per share. The company plans to request a hearing to present a compliance plan and seek an extension to meet listing requirements. However, there is no guarantee of approval or regaining compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
Rhea-AI Summary
NLS Pharmaceutics announced the closing of a registered direct offering of 7,000,000 common shares at $0.25 per share, raising $1.75 million. The company also issued unregistered warrants for 3,500,000 common shares at the same price. The proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
-
Rhea-AI Summary
NLS Pharmaceutics announces a registered direct offering of 7,000,000 common shares at $0.25 per share, along with a private placement of unregistered warrants to purchase up to 3,500,000 common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
Rhea-AI Summary
NLS Pharmaceutics (NLSP) announces a groundbreaking exclusive worldwide license agreement with Aexon Labs, Inc., acquiring global rights to Dual Orexin Receptor Agonists for neurological disorders. The agreement aims to develop compounds targeting orexin receptors for narcolepsy, hypersomnia, and neurodegenerative diseases. NLS plans to focus on disease-modifying compounds to enhance its neuroscience pipeline in sleep medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
none

FAQ

What is NLS Pharmaceutics Ltd focused on?

NLS Pharmaceutics Ltd specializes in developing life-improving drug therapies for rare and complex CNS disorders, focusing on neurobehavioral and neurocognitive disorders.

What are the lead products of NLS Pharmaceutics Ltd?

The company's lead products are Quilience, used for treating narcolepsy, and Nolazol, designed to address ADHD.

Where are the tangible assets of NLS Pharmaceutics Ltd held?

NLS Pharmaceutics Ltd's tangible assets are based in the United States.

What makes NLS Pharmaceutics Ltd's approach unique?

NLS Pharmaceutics Ltd stands out for its innovative solutions that cater to the unmet medical needs of patients with rare CNS disorders, promising life-improving drug therapies.

What are the key therapeutic areas NLS Pharmaceutics Ltd focuses on?

NLS Pharmaceutics Ltd concentrates on developing therapeutics for neurobehavioral and neurocognitive disorders, aiming to bring impactful treatments to those in need.

NLS Pharmaceutics AG

Nasdaq:NLSPW

NLSPW Rankings

NLSPW Stock Data

32.43M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Zurich